shelf(0)

No. 019 · GH & Growth · Muscle Growth

ACE-031

RamaterceptActRIIB-Fc

A Tier A · Controlled human trials how tiers work →
  • Not FDA approved
  • WADA ✗ S4
Compare Cite
Fingerprint no sequence
ACE-031 (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Quick answers

What is ACE-031?
A soluble activin receptor type IIB-Fc fusion protein that traps myostatin and related ligands. Fusion protein of the activin receptor IIB extracellular domain and an IgG1 Fc region, not a short peptide.
How strong is the evidence for ACE-031?
Tier A (controlled human trials) on the peptidemeta evidence scale. Randomized, placebo-controlled trials were run in healthy volunteers and boys with Duchenne muscular dystrophy; the DMD study was halted over safety signals.
Is ACE-031 FDA-approved?
No. ACE-031 is not approved by the FDA for any use.
Is ACE-031 banned in sport?
Yes. ACE-031 is prohibited in sport by the World Anti-Doping Agency under S4 (hormone and metabolic modulators).
How does ACE-031 work?
ACE-031 is a soluble ActRIIB-Fc fusion protein that acts as a ligand trap, binding and neutralizing myostatin, activin A, GDF-11, and other TGF-beta superfamily members before they can signal through cell-surface receptors. This broad ligand sequestration promotes robust muscle hypertrophy and reduces fat mass but also explains the off-target vascular effects.
What is known about the safety of ACE-031?
Phase II trials in Duchenne muscular dystrophy were halted due to epistaxis and telangiectasias (likely from BMP9/10 trapping affecting vascular biology). Lean mass gains were confirmed in humans.

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER A — At least one published randomized controlled trial in humans.

Randomized, placebo-controlled trials were run in healthy volunteers and boys with Duchenne muscular dystrophy; the DMD study was halted over safety signals.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Routes studied
Subcutaneous, Intravenous Routes used in published research
FDA
Not approved
WADA
Prohibited · S4 Hormone and metabolic modulators
04

Overview

A soluble activin receptor type IIB-Fc fusion protein that traps myostatin and related ligands. It was developed for muscle wasting but clinical trials were halted due to off-target effects.

Research status Phase II trials for Duchenne muscular dystrophy (halted due to epistaxis/telangiectasias); proof-of-concept demonstrated

05

Mechanism

ACE-031 is a soluble ActRIIB-Fc fusion protein that acts as a ligand trap, binding and neutralizing myostatin, activin A, GDF-11, and other TGF-beta superfamily members before they can signal through cell-surface receptors. This broad ligand sequestration promotes robust muscle hypertrophy and reduces fat mass but also explains the off-target vascular effects.

06

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Robust myostatin pathway inhibition
  • Significant lean mass gains in trials
  • Reduced fat mass
  • Potential bone mineral density improvement
07

Safety & unknowns

Phase II trials in Duchenne muscular dystrophy were halted due to epistaxis and telangiectasias (likely from BMP9/10 trapping affecting vascular biology). Lean mass gains were confirmed in humans. Demonstrates the risk of broad ligand-trap approaches. Not FDA-approved; development discontinued.

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [0]

No studies cited for this entry yet.

10

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

11

Cite this entry

$ cite --format=apa

peptidemeta. (2026). ACE-031. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/ace-031/

$ cite --format=bibtex 
@misc{peptidemeta-ace-031,
  title = {ACE-031},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/ace-031/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open